Who are Comparator: ceftriaxone + metronidazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-ceftriaxone-metronidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Comparator: ceftriaxone + metronidazole — Competitive Intelligence Brief

Comparator: ceftriaxone + metronidazole (Comparator: ceftriaxone + metronidazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic + nitroimidazole combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic + nitroimidazole combination Bacterial cell wall (ceftriaxone); anaerobic bacterial DNA (metronidazole) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: ceftriaxone + metronidazole (Comparator: ceftriaxone + metronidazole) — Merck Sharp & Dohme LLC. This is a fixed-dose combination of two antibiotics: ceftriaxone (a third-generation cephalosporin) inhibits bacterial cell wall synthesis, while metronidazole is a nitroimidazole that disrupts anaerobic bacterial DNA.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: ceftriaxone + metronidazole TARGET	Comparator: ceftriaxone + metronidazole	Merck Sharp & Dohme LLC	marketed	Beta-lactam antibiotic + nitroimidazole combination	Bacterial cell wall (ceftriaxone); anaerobic bacterial DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic + nitroimidazole combination class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: ceftriaxone + metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-ceftriaxone-metronidazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab